Ebola medical therapy: Difference between revisions
Marjan Khan (talk | contribs) No edit summary |
Marjan Khan (talk | contribs) |
||
| Line 8: | Line 8: | ||
==Medical Therapy== | ==Medical Therapy== | ||
:*'''Ebola virus treatment'''<ref>{{cite web|title=Ebola virus treatment|url=http://www.cdc.gov/vhf/ebola/treatment/index.html}}</ref><ref name="pmid21084112">{{cite journal| author=Feldmann H, Geisbert TW| title=Ebola haemorrhagic fever. | journal=Lancet | year= 2011 | volume= 377 | issue= 9768 | pages= 849-62 | pmid=21084112 | doi=10.1016/S0140-6736(10)60667-8 | pmc=PMC3406178 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21084112 }} </ref> | :*'''Ebola virus treatment'''<ref>{{cite web|title=Ebola virus treatment|url=http://www.cdc.gov/vhf/ebola/treatment/index.html}}</ref><ref name="pmid21084112">{{cite journal| author=Feldmann H, Geisbert TW| title=Ebola haemorrhagic fever. | journal=Lancet | year= 2011 | volume= 377 | issue= 9768 | pages= 849-62 | pmid=21084112 | doi=10.1016/S0140-6736(10)60667-8 | pmc=PMC3406178 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21084112 }} </ref> | ||
::*Preferred regimen: supportive therapy. There is no specific antiviral drug available for Ebola thus far. For information of investigational therapies including Favipiravir, Brincidofovir, ZMapp, TKM-Ebola, AVI-6002, and BCX4430, see [[Ebola future or investigational therapies|here]]. | |||
==Prophylaxis Against Co-infections or Super-infections== | ==Prophylaxis Against Co-infections or Super-infections== | ||
Revision as of 00:16, 5 May 2019
|
Ebola Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Postmortem Care |
|
Case Studies |
|
Ebola medical therapy On the Web |
|
American Roentgen Ray Society Images of Ebola medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Marjan Khan M.B.B.S.[2]
Overview
No specific antiviral drug has demonstrated effectiveness against Ebola infection. Management is primarily supportive and symptomatic. The following basic interventions, when used early, may improve the chances of survival: administration of intravenous fluids and correction of electrolyte abnormalities, maintenance of stable vital signs, and treatment against other co-infections or super-infections by antimicrobial agents. It is common practice to administer prophylactic broad-spectum antimicrobial agents, such as antibiotics and antimalarial agents, due to the high risk of co-infection or super-infection.
Medical Therapy
-
- Preferred regimen: supportive therapy. There is no specific antiviral drug available for Ebola thus far. For information of investigational therapies including Favipiravir, Brincidofovir, ZMapp, TKM-Ebola, AVI-6002, and BCX4430, see here.
Prophylaxis Against Co-infections or Super-infections
Overwhelming sepsis is associated with the majority of deaths due to Ebola virus disease.[3] Thus, it is common practice to administer antibiotics and antimalarial agents for patients with Ebola virus disease due to the high risk of co-infection or super-infection with Malaria and bacterial organisms.[4] In contrast, the administration of antiviral agents, such as acyclovir or ribavirin, has not demonstrated efficacy.[3]
Nutritional Support
- Although preferred, enteral nutrition may not be tolerated due to vomiting or paralytic ileus.
- Parental nutrition should be administered to patients who cannot tolerate oral food intake.
- Enteral nutrition should be resumed as soon as it is tolerated.
References
- ↑ "Ebola virus treatment".
- ↑ Feldmann H, Geisbert TW (2011). "Ebola haemorrhagic fever". Lancet. 377 (9768): 849–62. doi:10.1016/S0140-6736(10)60667-8. PMC 3406178. PMID 21084112.
- ↑ 3.0 3.1 Parkes-Ratanshi R, Ssekabira U, Crozier I (2014). "Ebola in West Africa: be aware and prepare". Intensive Care Med. 40 (11): 1742–5. doi:10.1007/s00134-014-3497-z. PMID 25253023.
- ↑ Kreuels B, Wichmann D, Emmerich P, Schmidt-Chanasit J, de Heer G, Kluge S; et al. (2014). "A Case of Severe Ebola Virus Infection Complicated by Gram-Negative Septicemia". N Engl J Med. doi:10.1056/NEJMoa1411677. PMID 25337633.